Ascentage Pharma Group Corp. Ltd. has priced the first IPO of the year in the U.S. The offering of 7.32 million shares has the Suzhou, China, and Rockville, Md.-based company looking for gross proceeds of about $126.4 million, assuming a price of $17.25 per share.
Janssen Pharmaceutica NV has divulged mucosa associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer.
Genescience Pharmaceuticals Co. Ltd. has synthesized cellular tumor antigen p53 (TP53) (Y220C mutant) reactivators reported to be useful for the treatment of cancer.
Kexing Biopharm Co. Ltd. has outlined progress in its cachexia and autoimmune pipelines, built upon its Kx-Body antibody technology platform and Kx-Fusion fusion protein technology platform.
Ymmunobio AG, in collaboration with the Paul Scherrer Institute, has received an Innosuisse grant to develop innovative radioactive loaded antibodies for the treatment and diagnosis of solid tumors based on Ymmunobio’s proprietary YB-800.
Adenoid cystic carcinoma (ACC) is a rare malignancy of the secretory glands with a high tendency to invade adjacent tissue and spread to the lung, bone or liver. No treatments other than surgery or radiotherapy are available, so new therapeutic strategies are urgently needed.
Neomorph Inc. has signed another billion-dollar deal to develop molecular glue degraders, this time with Abbvie Inc. It’s the third agreement in the past year the five-year-old company has signed with big pharma companies in a space with lots of collaborative deals.
Med-tech stocks experienced a turbulent year of ups and downs in 2024, as the BioWorld Med-Tech Stock Index saw lows of almost 15% and gains of nearly 5% before closing the year up 0.21%. This modest rebound follows consecutive declines of 4.44% in 2023 and a steep drop of 39.58% in 2022.
A year after its $175 million IPO in 2024, Arrivent Biopharma Inc. picked up rights to develop and commercialize Lepu Biopharma Co. Ltd.’s antibody-drug conjugate (ADC) candidate, MRG-007, worldwide excluding the greater China region.
RSS
